|
|
Teisinis statusas
Patentas neįsigaliojo (pagal Susitarimą)
| (51) | INT.CL. | C12N 9/10 | |
| C12N 15/54 | |||
| C07K 16/00 |
| (11) | Patento numeris | 2264151 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 10075271.6 |
| Europos patento paraiškos padavimo data | 2004-01-22 | |
| (97) | Europos patento paraiškos paskelbimo data | 2010-12-22 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2016-04-20 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (30) | Numeris | Data | Šalis |
| 441307 P | 2003-01-22 | US | |
| 491254 P | 2003-07-31 | US | |
| 495142 P | 2003-08-15 | US |
| (72) |
Umana, Pablo, CH
Bruenker, Peter, CH
Ferrara Koller, Claudia, CH
Suter, Tobias, CH
|
| (73) |
Roche Glycart AG,
Wagistrasse 18, 8952 Schlieren-Zuerich,
CH
|
| (54) | Fusion constructs and use of same to produce antibodies with increased FC receptor binding affinity and effector function |
| Fusion constructs and use of same to produce antibodies with increased FC receptor binding affinity and effector function |